GSK’s spin-off of Haleon was like shedding a weighted vest—since then, the pharma core has sprinted ahead. Q1 2024 sales jumped 10%, driven by blockbusters like Shingrix (£1.5 billion in sales) and HIV drugs. 😊 Its vaccine pipeline (21 candidates in Phase III) could be a golden goose, though patent cliffs remain a nagging concern. At a P/E of 10.5, GSK looks cheaper than rivals—but is it a value trap or a stealth growth play? The lab reports are at https://admiralmarkets.com/stocks/gsk